MY203136A - Plasminogen treatment of conditions associated with pai-1 overexpression - Google Patents

Plasminogen treatment of conditions associated with pai-1 overexpression

Info

Publication number
MY203136A
MY203136A MYPI2019007619A MYPI2019007619A MY203136A MY 203136 A MY203136 A MY 203136A MY PI2019007619 A MYPI2019007619 A MY PI2019007619A MY PI2019007619 A MYPI2019007619 A MY PI2019007619A MY 203136 A MY203136 A MY 203136A
Authority
MY
Malaysia
Prior art keywords
pai
overexpression
conditions associated
level
plasminogen
Prior art date
Application number
MYPI2019007619A
Other languages
English (en)
Inventor
Lyne Gagnon
Brigitte Grouix
Pierre Laurin
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of MY203136A publication Critical patent/MY203136A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019007619A 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression MY203136A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (1)

Publication Number Publication Date
MY203136A true MY203136A (en) 2024-06-10

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019007619A MY203136A (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Country Status (21)

Country Link
US (1) US11826404B2 (https=)
EP (1) EP3641888B1 (https=)
JP (1) JP2020524689A (https=)
KR (1) KR20200019217A (https=)
CN (1) CN110831668B (https=)
AU (1) AU2018287316B2 (https=)
BR (1) BR112019027229A2 (https=)
CA (1) CA3068153A1 (https=)
CL (1) CL2019003789A1 (https=)
DK (1) DK3641888T3 (https=)
ES (1) ES2965937T3 (https=)
FI (1) FI3641888T3 (https=)
IL (1) IL271470B2 (https=)
MX (1) MX2019015741A (https=)
MY (1) MY203136A (https=)
NZ (1) NZ760921A (https=)
RU (1) RU2020100080A (https=)
SG (1) SG11201912813SA (https=)
TW (1) TWI868051B (https=)
WO (1) WO2018234861A1 (https=)
ZA (1) ZA202000280B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107688A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
TWI787732B (zh) * 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
TW202342093A (zh) * 2020-03-24 2023-11-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
KR20220156934A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
WO2021190561A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
US20100028321A1 (en) 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
US11207387B2 (en) * 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
EP3556386A4 (en) 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING MEDICINALLY INDUCED KIDNEY INJURY

Also Published As

Publication number Publication date
JP2020524689A (ja) 2020-08-20
CN110831668A (zh) 2020-02-21
US11826404B2 (en) 2023-11-28
EP3641888B1 (en) 2023-10-11
BR112019027229A2 (pt) 2020-07-07
IL271470B2 (en) 2025-07-01
RU2020100080A (ru) 2021-07-23
IL271470A (en) 2020-01-30
CL2019003789A1 (es) 2020-07-10
DK3641888T3 (da) 2024-01-02
ZA202000280B (en) 2021-08-25
CA3068153A1 (en) 2018-12-27
AU2018287316A1 (en) 2020-02-06
RU2020100080A3 (https=) 2021-11-02
AU2018287316B2 (en) 2024-09-19
TWI868051B (zh) 2025-01-01
NZ760921A (en) 2026-01-30
MX2019015741A (es) 2020-11-11
TW201904990A (zh) 2019-02-01
EP3641888A4 (en) 2021-03-10
ES2965937T3 (es) 2024-04-17
KR20200019217A (ko) 2020-02-21
FI3641888T3 (fi) 2023-12-19
WO2018234861A1 (en) 2018-12-27
CN110831668B (zh) 2024-04-12
US20210330761A1 (en) 2021-10-28
EP3641888A1 (en) 2020-04-29
IL271470B1 (en) 2025-03-01
SG11201912813SA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MY203136A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
MX2018008709A (es) Uso terapeutico de inhibidores de activacion o estimulacion de celulas t.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
EP3344071A4 (en) COMBINED COMPOSITIONS FOR CONTROLLING BLOOD SUGAR MIRRORS, LIVER PROTECTION AND PREVENTING AND TREATING RELATED MEDICAL CONDITIONS
ZA201906153B (en) Pharmaceutical compositions for combination therapy
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
IL285160A (en) Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism
SG11201900796UA (en) Prophylactic or therapeutic agent for vascular disorder
SG10201907677QA (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.